How does IDYA's Q4 compare to past quarters?

IDEAYA Biosciences, Inc. (IDYA) has shown significant challenges in maintaining financial stability as evidenced by the company's quarterly revenue and net income trends over the past five years. 1. **Revenue Trends**: - IDYA's revenue has experienced growth from $7 million in 2024 Q4 to $50.93 million by 2022 Q4. - However, there was a slight dip to $27.94 million in 2021 Q4 before rebounding to $23.39 million in 2023 Q4. - The most recent data shows a decrease to $19.54 million in 2020 Q4, indicating a fluctuating revenue pattern with a low point in the company's financial performance. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q3||8967000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q4||1.0571E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q1||7247000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q2||8756000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q3|0.10036801605888257|8976000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q4|-71.9799451329108|2962000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q1|56.74072029805437|1.1359E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q2|-33.1772498857926|5851000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q3|230.87121212121212|2.9699E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q4|35.78663065496286|4022000|185| 2. **Net Income Trends**: - IDYA's net income has been negative for all quarters over the past five years, with the lowest being -$7 million in 2024 Q4 and the highest at -$112.96 million in 2023 Q4. - The net income for 2024 Q4 was -$274.48 million, which is the worst performing quarter in terms of net income. - The company has consistently faced financial challenges, with no quarter showing a positive net income, suggesting that IDYA is in a period of significant investment and potential financial strain. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q1|-25.854321245689206|-1.2043E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q2|-16.281906906906908|-1.2391E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q3|55.09162184337679|-4926000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2020 Q4|52.36991002689917|-5135000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q1|25.093415261977913|-9021000|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q2|11.653619562585748|-1.0947E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q3|-135.11977263499796|-1.1582E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2021 Q4|-254.66407010710807|-1.8212E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q1|-55.33754572663785|-1.4013E7|185| |IDYA|IDYA.O|IDEAYA Biosciences|2022 Q2|-101.47985749520416|-2.2056E7|185| In conclusion, while IDYA has shown some growth in revenue, the net income has been deeply negative, and the latest figures indicate a company under significant financial pressure. The fluctuating revenue pattern suggests that IDYA is facing challenges in maintaining a stable financial performance, which could be critical for its long-term sustainability and market position.